logo
Take Care

Take Care

Yahoo16-05-2025

Former Health Secretary and geriatrician David Scrase discusses New Mexico's aging population. (Photo provided by the New Mexico Health Care Authority)
David Scrase has worked as a geriatrician in New Mexico for nearly 30 years, and served several stints as the secretary of the Health and Human Services Departments. He is on the frontlines when it comes to treating older residents and their caregivers.
'This is a growing, giant issue,' Scrase told Source NM. 'I always tell people…I never go into a room where at least 80% of the people aren't trying to figure out what to do with an older person in their family who's going through something like this. It might not be their immediate family, but…everyone is on the verge of, or in the middle of, or just past having to make these kinds of decisions about how to provide care.'
Scrase started his practice in Michigan in 1981, relocated in 1998 to New Mexico and, he says, started concentrating on patients 75 and older in 2015. He also works as a clinical professor with the University of New Mexico Health Sciences Center.
Source NM spoke with Scrase recently about his concerns over aging health care and caregiving. The following interview has been edited for clarity and concision.
Source NM: What concerns do you have about the state of care for seniors in New Mexico?
David Scrase: New Mexico in the year 2000, we were ranked number 39th in the country in terms of the percent of people we had in our population that were 65 and older. And in 2030, according to some really reliable projections, we'll rank fourth.
NM Aging department commits to helping seniors age 'in place' and 'autonomously' in new draft plan
Seniors, in general, use about three times as many resources as people under 65, and so you've got this more than doubling of the senior population combined with three times the use rate. So there's going to be a dramatic growth of seniors and need for care for seniors.
There's also the fact that we have the number one poverty rate among people 65 and older, so we have the highest poverty rate for seniors. And poverty creates illness and complexity.
In the United States, over 6 million people are living with Alzheimer's disease. That's projected to more than double in the next 15 to 20 years. And over 11 million people are caregiving for dementia patients and they're providing 15 billion hours of free care. And in addition to having to really grow our healthcare facilities to manage all the growth in the population and their use of resources, we're going to have an issue with caregivers.
What are you seeing in your own practice?
Typically, we see people with dementia either coming in with their spouse, who probably is about the same age as them, and they're in their 80s and they're getting progressively less able to perform normal activities or daily living. So the natural history of Alzheimer's disease is a gradual decline and, therefore, how much caregiving they need is a gradual increase. As we have more Alzheimer's disease patients and they have this decline, more burden is placed on the families. And so it's extremely rare for me to see someone in their 80s not get completely worn out if they're the sole caregiver for a spouse or partner.
The most common group of people outside the home that become caregivers are, of course, daughters, which is about 50%, and then followed by daughters-in-law, which is estimated to be 40 to 45%, and so then the men get involved, unfortunately in the last 5 to 10%. And these caregivers, they're quitting their jobs. If they're from a big family, they set up some sort of elaborate rotation, but it's really, really hard to provide care at home for people who may be at the nursing home-level of care needed.
That is an economic consequence to their family, to the country, et cetera, et cetera, because Medicare doesn't pay a daughter to take care of her dad. They don't provide any help when Dad moves in with the family.
As a geriatrician, I'll have residents rotate with me, and I'll always say at the beginning of the session, because half of my patients maybe have dementia, I'll say, 'I want you to pay attention to, one, how advanced this patient's dementia is and, two, how much time do I spend talking to the patient versus how much time I spend talking to the caregiver.' And as people's dementia advances, I spend a lot more time making sure the caregiver's OK, that they have strategies to take care of themselves, that they can cope, because Alzheimer's disease, we don't have a lot of great treatments that really improve it. And if the caregiver collapses, then the whole system collapses. And so typically, the worse the dementia, the more time I spend with the caregivers.
What concerns have you heard from other New Mexico practitioners?
People are living longer and older people are becoming increasingly complex. I've seen a huge change from 1990. And so it's harder for some primary care doctors to manage the growing complexity of an 80-year-old's medical problems. If someone raises the question and someone has a memory issue, that's like a half hour of time that you have to figure out how to squeeze into a 20- or 30-minute appointment. And often it doesn't come up until halfway through and so doctors are scheduling people to come back for those assessments. But we're going to see more and more of it.
What advice do you give to family caregivers?
The number one thing is you need to take care of yourself first. And it's like you have this bucket of what you can scoop out every day of help to give to your loved one. And if your bucket's not full, it's not a long-term strategy. That's probably the biggest issue is getting people to accept the fact that to be an effective caregiver, the first thing they need to do is take care of themselves.
We have these things called the Six Activities of Daily Living: bathing, dressing, feeding, moving around, transferring, continence and going to the bathroom, and when people need help with two of those six, they qualify at the basic level for nursing home care, and there's families who're trying to provide three, four, five, sometimes six things at home. And so if it's clear that the family members are just not able to survive this, then I'll recommend that they improve the quality of time they spend with their loved one by putting them in a place where trained professionals can provide all this day-to-day medical care and support care and they can go and have quality time with their relative.
And then there's a middle one where they're not as bad as they need to be in a nursing home, but it's clear that we're on this downhill course. And I'll say, 'you need to have a plan B. I suggest you go out and look at some assisted living places or some graduated level of care places where you could be in assisted living and then go to a memory care unit maybe and then a nursing home.'
Most people focus on the question of whether or not they want to go to a nursing home, yes or no. And I don't think that—particularly as people get sicker and sicker— is a helpful question to ask. I think the question is, 'Do I want to go to a nursing home and accept the pros and cons of that choice, or do I want to keep mom at home and accept the pros and cons of that choice?' Because there are consequences whichever decision, and that's why I think I try to work with families to say, 'hey, this isn't something you need to decide to feel guilty about. You could really focus on the quality of the time you're spending with your loved one.'
This article was written with the support of a journalism fellowship from The Gerontological Society of America, The Journalists Network on Generations and The NIHCM Foundation.
SUBSCRIBE: GET THE MORNING HEADLINES DELIVERED TO YOUR INBOX

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Blood test for Alzheimer's could soon be available on the NHS
Blood test for Alzheimer's could soon be available on the NHS

Yahoo

time28 minutes ago

  • Yahoo

Blood test for Alzheimer's could soon be available on the NHS

A new blood test for Alzheimer's disease has been found to accurately detect early symptoms of the illness, according to new research. Experts from the Mayo Clinic in the US examined two proteins in blood plasma – amyloid beta 42/40 and p-tau217 – which are associated with amyloid plaque build-up, a hallmark of Alzheimer's disease, to provide further evidence that blood tests can accurately diagnose dementia. The study, which was carried out on more than 500 people in an outpatient memory clinic, found the blood test was highly accurate, with 95 per cent sensitivity. That means it was 95 per cent accurate in picking up people with memory problems, with very few cases missed. It was also 82 per cent for specificity, meaning it was also highly accurate in ruling out people without dementia. The blood test has already been approved by the Food and Drug Administration regulator in the US. Dr Gregg Day, who led the study in the Alzheimer's and Dementia journal, said the test was as good as more invasive tests currently in use. 'When performed in the outpatient clinical setting, this is similar to the accuracy of cerebrospinal fluid biomarkers of the disease and is much more convenient and cost-effective.' Overall, researchers found that p-tau217 levels were higher in patients with Alzheimer's disease versus those without the disease. Dr Day said the next steps in the research were to evaluate blood-based testing in more diverse patient populations and people with early Alzheimer's who show no cognitive symptoms. Dr Richard Oakley, associate director for research and innovation at the Alzheimer's Society in the UK, said the results 'suggest this test is very accurate' and could be used alongside other tests and observations from a trained health professional. 'While focused on Alzheimer's disease, the test was evaluated in people with other types of dementias too, showing that it may help with differentiate causes of cognitive decline – though more research in diverse groups of individuals and in community-based setting is still needed. 'Currently diagnosis options in the UK are often slow, expensive and can be invasive, meaning thousands miss out on the benefits one can bring. 'It's great to see blood tests like this approved for clinical use in the US – we hope to see the same in the NHS, which is why we're part of the Blood Biomarker Challenge.' The Blood Biomarker Challenge is a multi-million-pound research programme supported by the Alzheimer's Society, Alzheimer's Research UK and the National Institute for Health and Care Research. Its goal is to bring blood tests for dementia diagnosis to the NHS by 2029. Dr Julia Dudley, head of research at Alzheimer's Research UK, said: 'We urgently need to improve how we diagnose dementia and it's great to see international research working towards this goal. 'Blood tests in this study look at p-tau217 and amyloid beta 42/40, and showed the tests offered high accuracy in confirming Alzheimer's disease. 'This study adds to the growing evidence that blood tests can detect the diseases that cause dementia in people with early memory and thinking problems. 'An important point to consider is that people taking part in research don't always reflect the full diversity of those affected by dementia, who might have additional conditions or other characteristics. 'That is why work is needed to understand whether these blood tests work in a real-world setting.'

Alzheimer's blood test can accurately pick up early symptoms
Alzheimer's blood test can accurately pick up early symptoms

Yahoo

time5 hours ago

  • Yahoo

Alzheimer's blood test can accurately pick up early symptoms

A new blood test for Alzheimer's disease can accurately detect people with early symptoms, research suggests. Experts from the Mayo Clinic in the US have provided further evidence that blood tests can work to accurately diagnose dementia, by examining two proteins in blood plasma. These proteins – amyloid beta 42/40 and p-tau217 – are associated with amyloid plaque build-up, which is a hallmark of Alzheimer's disease. Researchers found the blood test was highly accurate, with 95% sensitivity, which means it was 95% accurate in picking up people with memory problems, with very few cases missed. It was also 82% for specificity, which means it was also highly accurate in ruling out people without dementia. The study was carried out on more than 500 people in an outpatient memory clinic, meaning it is real-world data. The blood test has already been approved by the Food and Drug Administration regulator in the US. Dr Gregg Day, who led the study in the Alzheimer's and Dementia journal, said the test was as good as more invasive tests currently in use. 'Our study found that blood testing affirmed the diagnosis of Alzheimer's disease with 95% sensitivity and 82% specificity,' he said. 'When performed in the outpatient clinical setting, this is similar to the accuracy of cerebrospinal fluid biomarkers of the disease and is much more convenient and cost-effective.' Overall, researchers found that p-tau217 levels were higher in patients with Alzheimer's disease versus those without the disease. Dr Day said the next steps in the research were to evaluate blood-based testing in more diverse patient populations and people with early Alzheimer's who show no cognitive symptoms. Dr Richard Oakley, associate director for research and innovation at the Alzheimer's Society in the UK, said the results 'suggest this test is very accurate' and could be used alongside other tests and observations from a trained health professional. "This study shows how blood tests are making diagnosis of Alzheimer's disease quicker, easier and more accessible than ever before in a real-world setting," he added. "While focused on Alzheimer's disease, the test was evaluated in people with other types of dementias too, showing that it may help with differentiate causes of cognitive decline – though more research in diverse groups of individuals and in community-based setting is still needed."

The Cause of Alzheimer's Might Be Coming From Within Your Mouth
The Cause of Alzheimer's Might Be Coming From Within Your Mouth

Yahoo

time6 hours ago

  • Yahoo

The Cause of Alzheimer's Might Be Coming From Within Your Mouth

In recent years, an increasing number of scientific investigations have backed an alarming hypothesis: Alzheimer's disease may not be merely a condition of an aging brain, but the product of infection. While the exact mechanisms of this infection are something researchers are still trying to isolate, numerous studies suggest the deadly spread of Alzheimer's goes way beyond what we used to think. One such study, published in 2019, suggested what could be one of the most definitive leads yet for a bacterial culprit behind Alzheimer's, and it comes from a somewhat unexpected quarter: gum disease. Watch the video below for a summary of their study: In a paper led by senior author Jan Potempa, a microbiologist from the University of Louisville, researchers reported the discovery of Porphyromonas gingivalis – the pathogen behind chronic periodontitis (aka gum disease) – in the brains of deceased Alzheimer's patients. It wasn't the first time the two factors have been linked, but the researchers went further. In separate experiments with mice, oral infection with the pathogen led to brain colonization by the bacteria, together with increased production of amyloid beta (Aβ), the sticky proteins commonly associated with Alzheimer's. The research team, coordinated by pharma startup Cortexyme, which was co-founded by first author Stephen Dominy, wasn't claiming to have discovered definitive evidence of Alzheimer's causation. But it was clear they thought we had a strong line of investigation here. P. gingivalis' gingipains (red) among neurons in the brain of a patient with Alzheimer's. (Cortexyme) "Infectious agents have been implicated in the development and progression of Alzheimer's disease before, but the evidence of causation hasn't been convincing," Dominy said at the time. "Now, for the first time, we have solid evidence connecting the intracellular, Gram-negative pathogen, P. gingivalis, and Alzheimer's pathogenesis." In addition, the team identified toxic enzymes called gingipains secreted by the bacteria in the brains of Alzheimer's patients, which correlated with two separate markers of the disease: the tau protein, and a protein tag called ubiquitin. But even more compellingly, the team identified these toxic gingipains in the brains of deceased people who were never diagnosed with Alzheimer's. That's important, because while P. gingivalis and the disease have been linked before, it's never been known – to put it simply – whether gum disease causes Alzheimers, or whether dementia leads to poor oral care. The fact that low levels of gingipains were evident even in people who were never diagnosed with Alzheimer's could be a smoking gun – suggesting they might have developed the condition if they had lived longer. "Our identification of gingipain antigens in the brains of individuals with AD and also with AD pathology but no diagnosis of dementia argues that brain infection with P. gingivalis is not a result of poor dental care following the onset of dementia or a consequence of late-stage disease, but is an early event that can explain the pathology found in middle-aged individuals before cognitive decline," the authors explained in their paper. Further, a compound formulated by the company called COR388, showed in experiments with mice that it could reduce bacterial load of an established P. gingivalis brain infection, while also reducing amyloid-beta production and neuroinflammation. We'll have to wait and see what future research will uncover about this link, but the research community is cautiously optimistic. "Drugs targeting the bacteria's toxic proteins have so far only shown benefit in mice, yet with no new dementia treatments in over 15 years it's important that we test as many approaches as possible to tackle diseases like Alzheimer's," chief scientific officer David Reynolds from Alzheimer's Research commented in a statement. The findings were reported in Science Advances. An earlier version of this story was published in January 2019. Common Diabetes Drug Linked to 'Exceptional Longevity' in Women Increased Toxicity Risk Identified For Children With ADHD, Autism Coffee Could Be The Secret to Healthy Aging For Women, Scientists Discover

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store